Biogen announced that Priya Singhal, M.D., M.P.H., currently Head of Global Safety and Regulatory Sciences and Interim Head of Research & Development, has been promoted to Executive Vice President, EVP, Head of Development, following a decision to separate Research and Development into two distinct functions that will both report directly to the CEO. In addition, Biogen has initiated a search for a new Executive Vice President, Head of Research; Dr. Singhal will serve as interim head of Research until a new leader is named.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
- Biogen Names Priya Singhal as Executive Vice President, Head of Development
- Needham health/pharmaceuticals analysts hold analyst/industry conference call
- Biogen, Alcoyne announce license, collaboration agreement
- Biogen (NASDAQ:BIIB) in Trouble Over Aduhelm Drug
- House Committee says FDA interactions with Biogen’ failed to follow’ protocol